Skip to main content
. Author manuscript; available in PMC: 2015 Jul 28.
Published in final edited form as: J Cancer Ther. 2011 Mar 31;2(1):22–39. doi: 10.4236/jct.2011.21004

Figure 10.

Figure 10

Relative anti-neoplastic potency of covalent epirubicin-(C13-imino)-[anti-HER2/neu] immunochemothe-rapeutic compared to monoclonal immunoglobulin anti-HER2/neu and anti-EGFR fractions against chemotherapeutic-resistant SKBr-3 mammary carcinoma. Legend: (◆) covalent epirubicin-(C13-imino)-[anti-HER2/neu] immuno-chemotherapeutic; (∎) anti-HER2/neu monoclonal antibody; and (▲) anti-EGFR monoclonal antibody. Monolayers of SKBr-3 mammary carcinoma were incubated with immunochemotherapeutics over a 72-hour period and cytotoxicity measured as a function of MTT cell vitality relative to matched negative reference controls.